Overview

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials

Status:
Completed
Trial end date:
2017-10-18
Target enrollment:
Participant gender:
Summary
This registry will be used to identify patients who have etiology diagnosed or suspected to be Alzheimer's disease and positive amyloid scans, and have indicated their interest in being contacted for an Eli Lilly and Company (Lilly) Alzheimer's Disease drug research trial.
Details
Lead Sponsor:
Avid Radiopharmaceuticals
Collaborators:
Eli Lilly and Company
PRA Health Sciences